PUBLISHER: Lucintel | PRODUCT CODE: 1263909
PUBLISHER: Lucintel | PRODUCT CODE: 1263909
Cell & Gene Therapy Manufacturing Service Market Trends and Forecast
The future of the cell & gene therapy manufacturing service market looks promising with opportunities in cell processing, cell banking, process development, fill & finish operations, analytical and quality testing, raw material testing, and vector production. The global cell & gene therapy manufacturing service market is expected to reach an estimated $20.5 billion by 2028 with a CAGR of 22.1% from 2023 to 2028. The major drivers for this market are a growing number of cancer cases and rare diseases and increasing research and development spending in pharmaceutical companies.
Cell & Gene Therapy Manufacturing Service Market by Therapy Type, Scale, Mode, Workflow, and Region,
A more than 150-page report is developed to help in your business decisions. A sample figure with some insights is shown below.
Cell & Gene Therapy Manufacturing Service Market by Segments
Cell & Gene Therapy Manufacturing Service Market by Segment
Cell & Gene Therapy Manufacturing Service Market by Therapy Type [Value ($B) Shipment Analysis from 2017 to 2028]:
Cell Therapy
Stem Cell Therapy
Non-Stem Cell Therapy
Gene Therapy
Cell & Gene Therapy Manufacturing Service Market by Scale [Value ($B) Shipment Analysis from 2017 to 2028]:
Pre-Commercial/ R&D Scale
Commercial Scale
Cell & Gene Therapy Manufacturing Service Market by Mode [Value ($B) Shipment Analysis from 2017 to 2028]:
Contract
In-House
Cell & Gene Therapy Manufacturing Service Market by Workflow [Value ($B) Shipment Analysis from 2017 to 2028]:
Cell Processing
Cell Banking
Process Development
Fill & Finish Operations
Analytical and Quality Testing
Raw Material Testing
Vector Production
Others
Cell & Gene Therapy Manufacturing Service Market by Region [Value ($B) Shipment Analysis from 2017 to 2028]:
North America
Europe
Asia Pacific
The Rest of the World
List of Cell & Gene Therapy Manufacturing Service Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, cell & gene therapy manufacturing service companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cell & gene therapy manufacturing service companies profiled in this report include-
Lonza
Bluebird Bio
Catalent
Roche
Samsung Biologics
Cell & Gene Therapy Manufacturing Service Market Insights
Lucintel forecasts that cell therapy will remain the larger therapy type segment over the forecast period due to increasing adoption of this therapy in treating diseases, such as cancer, autoimmune, urinary, and infectious issues.
Process development is expected to remain the largest segment due to growing number of therapies proceeding from clinical trials to regulatory approval.
North America will remain the largest region due to the increasing number of gene and cell therapy research and development firms, along with increasing elderly population and rising cases of infectious diseases in the region.
Features of the Cell & Gene Therapy Manufacturing Service Market
Market Size Estimates: Cell & gene therapy manufacturing service market size estimation in terms of value ($B)
Trend And Forecast Analysis: Market trends (2017-2022) and forecast (2023-2028) by various segments and regions.
Segmentation Analysis: Cell & gene therapy manufacturing service market size by various segments, such as therapy type, scale, mode, workflow, and region
Regional Analysis: Cell & gene therapy manufacturing service market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.
Growth Opportunities: Analysis on growth opportunities in different therapy types, scales, modes, workflows, and regions for the cell & gene therapy manufacturing service market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape for the cell & gene therapy manufacturing service market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the cell & gene therapy manufacturing service market size?
Answer: The global cell & gene therapy manufacturing service market is expected to reach an estimated $20.5 billion by 2028.
Q2. What is the growth forecast for cell & gene therapy manufacturing service market?
Answer: The global cell & gene therapy manufacturing service market is expected to grow with a CAGR of 22.1% from 2023 to 2028.
Q3. What are the major drivers influencing the growth of the cell & gene therapy manufacturing service market?
Answer: The major drivers for this market are a growing number of cancer cases and rare diseases and increasing research and development spending in pharmaceutical companies.
Q4. What are the major segments for cell & gene therapy manufacturing service market?
Answer: The future of the cell & gene therapy manufacturing service market looks promising with opportunities in cell processing, cell banking, process development, fill & finish operations, analytical and quality testing, raw material testing, and vector production.
Q5. Who are the key cell & gene therapy manufacturing service companies?
Answer: Some of the key cell & gene therapy manufacturing service companies are as follows:
Lonza
Bluebird Bio
Catalent
Roche
Samsung Biologics
Q6. Which cell & gene therapy manufacturing service segment will be the largest in future?
Answer: Lucintel forecasts that cell therapy will remain the larger therapy type segment over the forecast period due to increasing adoption of this therapy in treating diseases, such as cancer, autoimmune, urinary, and infectious issues.
Q7. In cell & gene therapy manufacturing service market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region due to the increasing number of gene and cell therapy research and development firms, along with increasing elderly population and rising cases of infectious diseases in the region.
Q8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% Customization Without any Additional Cost.